Hubungan Rasionalitas Penggunaan Antibiotik terhadap Luaran Klinis Pasien Pneumonia Komunitas Rawat Inap
Abstract
Pneumonia is a lung parenchyma disease caused by bacteria, fungi, viruses, and parasites. Irrational use of antibiotics will lead to antibiotic resistance, so the goal of therapy has yet to be achieved. This study evaluates the rationality of using community antibiotics for the clinical outcome of community pneumonia patients in RSUD. Dr. H. Abdul Moeloek.This research is descriptive-analytic with a cross-sectional design and retrospective data retrieval from medical records in 2019. The data analysis was carried out descriptively, and the correlation analysis of the rationale of antibiotic use with clinical outcomes using the Spearman test. The study's results of 144 analyzed showed the characteristics of community pneumonia patients, 78 male, and 66 female patients. The evaluation of the use of antibiotics using the ATC/DDD method showed that Ceftriaxon DDD was 46.80 DDD/100 patient-days, Azithromycin (23.91 DDD/100 patient-days), Levofloxacin (22.70 DDD/100 patient-days). With the Gyssen method, patients used antibiotics correctly (category 0) by 72.91% and incorrectly (categories I – VI) by 27.09%. Statistical analysis showed a significant relationship (p-value=0.003) between the rational use of antibiotics and patient clinical outcomes. Further research is needed regarding the incidence of Drugs Related Problems on the clinical effects of community pneumonia patients.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 66 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.